Extramedullary disease in APL: a real phenomenon to contend with or not?

Chezi Ganzel, Dan Douer

Journal: Best practice & research. Clinical haematology 2015;27(1):63-8

PMID: 24907018

Full Text on Elsevier Science View on PubMed

Abstract

In the last 2 decades an increasing number of patients reported with extramedullary involvement among relapsed acute promyelocytic leukemia (APL) patients. Several investigators related this phenomenon to the relatively new treatment of all-trans-retinoic-acid (ATRA). In this review article we will examine what has been reported in the medical literature on extramedullary disease in APL: the common sites to be involved, the clinical risk factors to its development, the role of ATRA and arsenic tri-oxide and the recommended treatment.

Address: Shaare Zedek Medical Center, Jerusalem, Israel; Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA. Electronic address: [email protected].; Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA; Weil Cornell Medical College, NYC, USA. Electronic address: [email protected].

DOI: 10.1016/j.beha.2014.04.001

Link outs

Free resources

Other Literature Sources:

https://scite.ai/reports/24907018

Subscription / membership required

Full Text Sources:

MeSH Terms: Antineoplastic Combined Chemotherapy Protocols, Arsenic Trioxide, Arsenicals, Benzoates, Cerebral Hemorrhage, Humans, Incidence, Leukemia, Promyelocytic, Acute, Leukemic Infiltration, Models, Biological, Multicenter Studies as Topic, Organ Specificity, Oxides, Prognosis, Randomized Controlled Trials as Topic, Remission Induction, Risk Factors, Tetrahydronaphthalenes, Tretinoin